Neurometrix (NASDAQ:NURO) has received an average broker rating score of 3.00 (Hold) from the one analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation.
Zacks has also assigned Neurometrix an industry rank of 177 out of 255 based on the ratings given to its competitors.
Separately, ValuEngine lowered shares of Neurometrix from a “buy” rating to a “hold” rating in a report on Wednesday, April 18th.
Neurometrix (NASDAQ:NURO) last announced its quarterly earnings data on Friday, April 20th. The medical device company reported $0.08 earnings per share for the quarter. Neurometrix had a negative net margin of 47.75% and a negative return on equity of 161.28%. The business had revenue of $4.94 million for the quarter.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Thompson Davis & CO. Inc. raised its holdings in Neurometrix by 114.0% in the first quarter. Thompson Davis & CO. Inc. now owns 90,647 shares of the medical device company’s stock worth $128,000 after purchasing an additional 48,291 shares during the period. Renaissance Technologies LLC raised its holdings in Neurometrix by 68.2% in the fourth quarter. Renaissance Technologies LLC now owns 123,783 shares of the medical device company’s stock worth $214,000 after purchasing an additional 50,200 shares during the period. Finally, Sabby Management LLC raised its holdings in Neurometrix by 92.4% in the fourth quarter. Sabby Management LLC now owns 180,039 shares of the medical device company’s stock worth $310,000 after purchasing an additional 86,478 shares during the period. Institutional investors and hedge funds own 14.67% of the company’s stock.
Neurometrix Company Profile
NeuroMetrix, Inc, a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurometrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurometrix and related companies with MarketBeat.com's FREE daily email newsletter.